Pharmacyclics, Inc. (NASDAQ:PCYC)
CAPS Rating:
A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.
A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.
Recs
The b-cell cancer drug they have in trial was found not to have positiveresults at the dosage being tested.